Satoshi Igawa

10PUBLICATIONS
7CO-AUTHORS
Radiation therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Nov 28, 2023
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).

Ou Yamaguchi, Keita Mori, Saori Takata

|Nov 22, 2021
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.

Satoshi Igawa, Tomoya Fukui, Masashi Kasajima

|Aug 20, 2021
Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease.

Satoshi Igawa, Masanori Yokoba, Akira Takakura

|Apr 01, 2021
Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy.

Seiichiro Kusuhara, Satoshi Igawa, Masaaki Ichinoe

|Feb 15, 2020
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.

Tomoya Fukui, Shinji Hosotani, Itaru Soda

|Oct 05, 2019
Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma.

Yasuhiro Hiyoshi, Yuichi Sato, Masaaki Ichinoe

Pageof 2

Frequent Collaborators

3 joint publications

Tomoya Fukui

2 joint publications

Yuichi Sato

1 joint publications

Katsuhiko Naoki

1 joint publications

Ou Yamaguchi